Self Study 2023 Release I: Antifungal Prophylaxis in AML Therapy
AML is a hematologic malignancy that can induce profound and prolonged neutropenia, placing patients at risk for infectious complications. Invasive fungal infections (IFI) are a major cause of morbidity and mortality in leukemia, with mortality reported as high as 60%1,2. In 2007 posaconazole replaced fluconazole as the standard for prophylaxis in patients receiving remission induction chemotherapy3. Optimal antifungal prophylaxis for low-intensity regimens and with novel therapies remains controversial
System Requirements
All online, interactive modules require a computer and a reliable internet connection.
If you have questions about these modules, please contact HOPA Education at education@hoparx.org.
Accreditation Statement
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by MAY 1, 2024.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of Board Certified Oncology Pharmacist (BCOP) credit. A BCOP statement of credit will be issued only upon completion of a post- activity evaluation form, and post-test, a passing grade of 75% or greater is achieved. BCOP credit must be claimed by MAY 1, 2024.
Disclosure of Conflicts of Interest
The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict
The Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.